Clinical Trial Update: Residual Plasma Concentration of Sorafenib and Adverse Events in CHC

View source ↗

Summary

The update discusses residual plasma concentrations of sorafenib and related adverse events in patients with advanced or metastatic hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: University Hospital, Caen | Conditions: Advanced or Metastatic Hepatocellular Carcinoma | Status: UNKNOWN